All In MedTech

FDA Clearance Tracker · P130029-S002

FLUENCY PLUS ENDOVASCULAR STENT GRAFT

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Apr 26, 2016 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Apr 26, 2016

Approved

Time to decision

361 days

Received May 1, 2015. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P130029-S002
Device name
FLUENCY PLUS ENDOVASCULAR STENT GRAFT
Applicant location
Tempe, AZ
Received
May 1, 2015
Decided
Apr 26, 2016
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P130029

Device type

Device class
Class III

Every decision under product code PFV

FDA's approval statement

As written in FDA's record.

Approval for the Fluency Plus Endovascular Stent Graft. This device is indicated for use in the treatment of in-stent restenosis in the venous outflow of hemodialysis patients dialyzing by either an arteriovenous (AV) fistula or AV graft and for the treatment of stenosis in the venous outflow of hemodialysis patients dialyzing by an AV graft.

Source documents

Other decisions for Bard Peripheral Vascular, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.